Research programme: movement disorder therapeutics - Nine Square Therapeutics
Latest Information Update: 17 Jan 2022
At a glance
- Originator Nine Square Therapeutics
- Class Small molecules
- Mechanism of Action MCOLN1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Movement disorders